No Weight Loss in the First Month on GLP-1: What Research Can Tell You

If you've been on a GLP-1 medicine for a few weeks and the scale has barely moved, it's completely understandable to feel deflated. Online stories can make it look as though big changes should happen straight away. In reality, responses vary a lot, and the first month is a very short window for judging a long-term treatment.

You're probably still on a starter dose

Most weekly injectable medicines start low and step up gradually to help people tolerate them. In the US labels:

• Wegovy starts at 0.25 mg once weekly for 4 weeks, then increases every 4 weeks toward the usual 2.4 mg maintenance dose.
• Zepbound starts at 2.5 mg once weekly for 4 weeks, then increases in 2.5 mg steps (after at least 4 weeks each) to a maintenance dose of 5, 10 or 15 mg.

So the first month usually isn't the dose that produced the big averages in clinical trials. In the STEP 1 trial of Wegovy, for example, the average loss of about 15% was measured at week 68—well over a year in. Your prescriber decides how and when to adjust the dose, partly based on how you're tolerating it.

Why the first few weeks can look different

Scale weight moves for lots of reasons that have nothing to do with fat: fluid shifts, salt, bowel contents (constipation is common on these medicines), menstrual cycles, activity and normal day-to-day ups and downs. Our explainer on why weight changes day to day covers this. Some people notice appetite changes early; others notice little at first. Neither an early appetite change nor a single weigh-in can predict how treatment will turn out.

What does the research say about response?

A 2026 systematic review in Obesity Reviews looked at why some people lose less on GLP-1 and GIP-based medicines. Factors linked with smaller responses included higher starting weight or BMI, higher HbA1c and insulin resistance, male sex and older age, while sticking with treatment over more months was linked with more weight loss. These are group-level associations, not a checklist that explains any one person's result.

Real-world results can also differ from trials. In a US health-system study of 853 people prescribed a GLP-1 for class 2–3 obesity, about a quarter never started the medicine and over a third stopped within two years—the most common reasons were losing contact with the prescriber, side effects and loss of insurance coverage. Those who stayed on treatment for two years lost an average of about 9% of their weight, with wide variation. Trial averages describe defined groups; they aren't a promised timeline for you.

What to track without obsessing

If weighing is part of your care plan, weigh under consistent conditions and look at the trend over several weeks rather than treating each reading as a verdict—a weight trend calculator can help. Note your dose dates, side effects, appetite, how well you're eating and drinking, and any missed doses. Tracking supports a follow-up conversation; it shouldn't replace your clinician's assessment or push you toward unsafe restriction.

When to talk to your prescriber

Ask how long your current phase is expected to last, what response they'll look for, and when the plan will be reviewed. Please don't increase the dose, shorten the gap between doses, or add other weight-loss products on your own. And if you have severe side effects, can't keep food or fluids down, or just feel unwell, contact your care team rather than waiting for the scale to change.

A quiet first month is information to discuss—not a verdict on your effort or your future results.